Trial studying safety and effects for Multiple Myeloma
Official title A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
ClinicalTrials.gov ID: NCT06988488
What this study is testing
What is Elranatamab?
An investigational injectable medicine being studied as a potential treatment for relapsed and refractory multiple myeloma. It is designed to bind to BCMA on myeloma cells and CD3 on T cells, directing the immune system to attack the cancer cells.
Also referred to as Elrexfio, PF-0686313.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find the best dose and schedule for two drugs used together. It also checks if the treatment is safe and if it helps shrink tumors.
- Who it's for
- People with multiple myeloma that has returned or stopped responding to other treatments.
- What's involved
- Participants will take mezigdomide and elranatamab. They will have regular checkups and tests to monitor their health and how the drugs are working.
- Time commitment
- The study duration and specific visit schedule are not listed in the provided text.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 with history of relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3...
- Measurable MM by local laboratory.
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
- Adherence to contraception requirements.
You likely can't join if
- Prior treatment with mezigdomide.
- Prior treatment with T cell engaging or T cell engager (TCE).
- Prior treatment with B cell-maturation antigen (BCMA)-targeting therapy, with the exception of participants who have received autologous...
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- New Haven, Connecticut, United States
- Hackensack, New Jersey, United States
- Houston, Texas, United States
- Calgary, Alberta, Canada
- Halifax, Nova Scotia, Canada
- Toronto, Ontario, Canada
- Shanghai, Shanghai Municipality, China
- Dresden, Germany
- Hamburg, Germany
- Heidelberg, Germany
- Athens, Attikí, Greece
- Trondheim, Sør-Trøndelag, Norway
- Oslo, Norway
- Santander, Cantabria, Spain
- Salamanca, Spain
- London, England, United Kingdom
- London, Sutton, United Kingdom
- Manchester, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; New Haven, Connecticut, United States; Hackensack, New Jersey, United States; Houston, Texas, United States; Calgary, Alberta, Canada; Halifax, Nova Scotia, Canada and 13 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.